223 related articles for article (PubMed ID: 36546346)
41. Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.
Bieber T; Thyssen JP; Irvine AD; Tsunemi Y; Chen YF; Sun L; Schloebe A; Riedl E; Cork MJ
Clin Exp Dermatol; 2023 Jul; 48(8):881-888. PubMed ID: 37032446
[TBL] [Abstract][Full Text] [Related]
42. Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5).
Rosmarin D; Casillas M; Chen S; Dawson Z; Pierce E; Zhang H; Bukhalo M; Smith S
J Cutan Med Surg; 2022; 26(3):262-266. PubMed ID: 35086348
[TBL] [Abstract][Full Text] [Related]
43. Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores.
Wollenberg A; Simon D; Kulthanan K; Figueras-Nart I; Misery L; Tangsirisap N; Spina L; Lu N; Grond S; Eyerich K
J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):695-702. PubMed ID: 38041556
[TBL] [Abstract][Full Text] [Related]
44. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
Guttman-Yassky E; Silverberg JI; Nemoto O; Forman SB; Wilke A; Prescilla R; de la Peña A; Nunes FP; Janes J; Gamalo M; Donley D; Paik J; DeLozier AM; Nickoloff BJ; Simpson EL
J Am Acad Dermatol; 2019 Apr; 80(4):913-921.e9. PubMed ID: 29410014
[TBL] [Abstract][Full Text] [Related]
45. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
46. The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.
Yoon S; Kim K; Shin K; Kim HS; Kim B; Kim MB; Ko HC; Kim YH
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):52-61. PubMed ID: 37597261
[TBL] [Abstract][Full Text] [Related]
47. Baricitinib: A Review in Moderate to Severe Atopic Dermatitis.
Hoy SM
Am J Clin Dermatol; 2022 May; 23(3):409-420. PubMed ID: 35503162
[TBL] [Abstract][Full Text] [Related]
48. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
Silverberg JI; DeLozier A; Sun L; Thyssen JP; Kim B; Yosipovitch G; Nunes FP; Gugiu PC; Doll HA; Eichenfield LF
Health Qual Life Outcomes; 2021 Oct; 19(1):247. PubMed ID: 34688290
[TBL] [Abstract][Full Text] [Related]
49. Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry.
Boesjes CM; Kamphuis E; Zuithoff NPA; Bakker DS; Loman L; Spekhorst LS; Haeck I; Kamsteeg M; Van Lynden-van Nes AMT; Garritsen FM; Politiek K; Oldhoff M; De Graaf M; Schuttelaar MLA; De Bruin-Weller MS
Acta Derm Venereol; 2022 Nov; 102():adv00820. PubMed ID: 36420885
[TBL] [Abstract][Full Text] [Related]
50. Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.
Guttman-Yassky E; Thyssen JP; Silverberg JI; Papp KA; Paller AS; Weidinger S; Chih-Ho Hong H; Hendrickson B; Dilley D; Tenorio AR; Ladizinski B; Chu AD; Liu J; Irvine AD
J Allergy Clin Immunol; 2023 Jan; 151(1):172-181. PubMed ID: 36195170
[TBL] [Abstract][Full Text] [Related]
51. Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.
Rosmarin D; Fretzin S; Strowd L; Casillas M; DeLozier AM; Dawson Z; Chen S; Lu N; Thyssen JP
J Cutan Med Surg; 2022; 26(4):377-385. PubMed ID: 35354410
[TBL] [Abstract][Full Text] [Related]
52. An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis.
Mendes JT; Balogh EA; Strowd LC; Feldman SR
Expert Opin Pharmacother; 2020 Jun; 21(9):1027-1033. PubMed ID: 32208940
[TBL] [Abstract][Full Text] [Related]
53. Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.
Morand E; Smolen JS; Petri M; Tanaka Y; Silk M; Dickson C; Meszaros G; de la Torre I; Issa M; Zhang H; Dörner T
RMD Open; 2023 Aug; 9(3):. PubMed ID: 37604638
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of baricitinib for the treatment of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis of randomized clinical trials.
Wang B; Pan S; Yao Y; Zeng L; Zhang G
Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1139-1149. PubMed ID: 35876397
[TBL] [Abstract][Full Text] [Related]
55. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
56. Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
Sandborn WJ; D'Haens GR; Sands BE; Panaccione R; Ng SC; Lawendy N; Kulisek N; Modesto I; Guo X; Mundayat R; Su C; Vranic I; Panés J
J Crohns Colitis; 2023 Apr; 17(3):338-351. PubMed ID: 36124702
[TBL] [Abstract][Full Text] [Related]
57. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
58. Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7.
Masuda K; Delozier AM; Kolodsick J; Buchanan A; Pink AE; Sun L; Wang Z; Stingeni L; Thac I D
Eur J Dermatol; 2022 Apr; 32(2):237-243. PubMed ID: 35866910
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis.
Narla S; Silverberg JI
Dermatitis; 2024; 35(S1):S24-S38. PubMed ID: 37527229
[No Abstract] [Full Text] [Related]
60. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Wallace DJ; Furie RA; Tanaka Y; Kalunian KC; Mosca M; Petri MA; Dörner T; Cardiel MH; Bruce IN; Gomez E; Carmack T; DeLozier AM; Janes JM; Linnik MD; de Bono S; Silk ME; Hoffman RW
Lancet; 2018 Jul; 392(10143):222-231. PubMed ID: 30043749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]